EA202190167A1 - Замещенные фенилоксазолидиноны для антимикробной терапии - Google Patents

Замещенные фенилоксазолидиноны для антимикробной терапии

Info

Publication number
EA202190167A1
EA202190167A1 EA202190167A EA202190167A EA202190167A1 EA 202190167 A1 EA202190167 A1 EA 202190167A1 EA 202190167 A EA202190167 A EA 202190167A EA 202190167 A EA202190167 A EA 202190167A EA 202190167 A1 EA202190167 A1 EA 202190167A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antimicrobial therapy
substituted phenyloxazolidinones
phenyloxazolidinones
substituted
spirocyclic
Prior art date
Application number
EA202190167A
Other languages
English (en)
Inventor
Кристофер Б. Купер
Хайхун Хуан
Дунфэн Чжан
Надер Фотухи
Такуси Канеко
Original Assignee
Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. filed Critical Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк.
Publication of EA202190167A1 publication Critical patent/EA202190167A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Abstract

Изобретение относится к новым оксазолидинонам (формула I)или их фармацевтически приемлемым солям, содержащим кольцо А, характеризующееся N-содержащими моноциклическими, бициклическими или спироциклическими заместителями, к их получению и их применению в качестве лекарственных средств для лечения Mycobacterium tuberculosis и других микробных инфекций, отдельно или в комбинации с другими противоинфекционными средствами лечения.
EA202190167A 2015-07-17 2016-07-15 Замещенные фенилоксазолидиноны для антимикробной терапии EA202190167A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562193963P 2015-07-17 2015-07-17

Publications (1)

Publication Number Publication Date
EA202190167A1 true EA202190167A1 (ru) 2021-07-30

Family

ID=57834866

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202190167A EA202190167A1 (ru) 2015-07-17 2016-07-15 Замещенные фенилоксазолидиноны для антимикробной терапии
EA201792566A EA037643B1 (ru) 2015-07-17 2016-07-15 Замещенные фенилоксазолидиноны для антимикробной терапии

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201792566A EA037643B1 (ru) 2015-07-17 2016-07-15 Замещенные фенилоксазолидиноны для антимикробной терапии

Country Status (13)

Country Link
US (2) US10550092B2 (ru)
EP (2) EP3932917A3 (ru)
JP (4) JP6786598B2 (ru)
KR (1) KR102511898B1 (ru)
CN (2) CN108348507B (ru)
AU (3) AU2016295165B2 (ru)
BR (1) BR112018000991A2 (ru)
CA (1) CA2990260A1 (ru)
EA (2) EA202190167A1 (ru)
ES (1) ES2897973T3 (ru)
HK (1) HK1255105A1 (ru)
WO (1) WO2017015106A1 (ru)
ZA (1) ZA201800189B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102511898B1 (ko) * 2015-07-17 2023-03-20 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 항미생물 요법을 위한 치환된 페닐옥사졸리디논
CN108727406B (zh) * 2017-03-28 2021-12-07 北京协和制药二厂 含氮杂环取代的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CN112543756A (zh) 2018-07-25 2021-03-23 卡迪拉保健有限公司 用于治疗哺乳动物感染的经取代噁唑烷酮类
WO2020147504A1 (en) * 2019-01-18 2020-07-23 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
WO2020234636A1 (en) 2019-05-17 2020-11-26 Cadila Healthcare Limited Novel compounds for the treatment of mammalian infections
CN110922411B (zh) * 2019-11-27 2021-06-04 合肥远志医药科技开发有限公司 一种药物中间体的合成方法
WO2021184339A1 (en) * 2020-03-20 2021-09-23 Merck Sharp & Dohme Corp. Oxazolidinone compound and methods of use thereof as an antibacterial agent
CN113999152B (zh) * 2021-07-14 2023-05-09 上海凌富药物研究有限公司 一种顺式-1-苄基-2,4-二烷氧基羰基氮杂环丁烷的合成方法
WO2024035618A1 (en) * 2022-08-10 2024-02-15 Merck Sharp & Dohme Llc Processes for preparing oxazolidinone compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) * 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5952324A (en) * 1994-11-15 1999-09-14 Pharmacia & Upjohn Company Bicyclic oxazine and thiazine oxazolidinone antibacterials
PT828741E (pt) * 1995-05-11 2002-02-28 Upjohn Co Oxazolidinonas de diazinilo espirociclico e biciclico e de carbazinilo
US6255304B1 (en) * 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
CA2351062A1 (en) * 1998-11-27 2000-06-08 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
EP1451164A2 (en) * 2001-07-12 2004-09-01 PHARMACIA & UPJOHN COMPANY Amide derivatives having improved solubility
IL163688A0 (en) 2002-02-28 2005-12-18 Astrazeneca Ab 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and theiruse as antibacterial agents
AU2003224345A1 (en) * 2002-04-30 2003-11-17 Orchid Chemicals & Pharmaceuticals Antibacterial agents
TW200403240A (en) 2002-06-28 2004-03-01 Upjohn Co Difluorothioacetamides of oxazolidinones as antibacterial agents
US6875784B2 (en) * 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
CN1237056C (zh) * 2002-12-25 2006-01-18 中国科学院上海药物研究所 噁唑烷酮类化合物、其制备方法和用途
MXPA06002188A (es) * 2003-08-25 2006-04-27 Warner Lambert Co Nuevos compuestos antimicrobianos de ariloxazolidinona.
WO2006056875A1 (en) * 2004-11-29 2006-06-01 Pharmacia & Upjohn Company Llc Thiazepine oxazolidinones as antibacterial agents
US7332611B2 (en) * 2005-05-06 2008-02-19 University Of South Florida N-thiolated 2 oxazolidone antibiotics
CA2610978A1 (en) * 2005-06-29 2007-01-04 Pharmacia & Upjohn Company Llc Homomorpholine oxazolidinones as antibacterial agents
EP1902048A1 (en) 2005-07-06 2008-03-26 Pharmacia & Upjohn Company LLC Oxazolidinone carboxamides containing azetidine and cyclobutane as antibacterial agents
BRPI0909028A2 (pt) * 2008-03-26 2015-09-22 Global Alliance For Tb Drug Dev nitroimidazóis bicíclicos covalentemente ligados a fenil oxazolidinonas substituídas, composições farmacêuticas e uso dos mesmos
KR100980681B1 (ko) * 2008-09-16 2010-09-07 한국과학기술연구원 디플루오로페닐 유도체를 갖는 신규한 옥사졸리디논 유도체또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 하는 항생제 조성물
US20110053916A1 (en) * 2009-08-14 2011-03-03 Vertex Pharmaceuticals Incorporated Pyrimidine compounds as tuberculosis inhibitors
KR102511898B1 (ko) * 2015-07-17 2023-03-20 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 항미생물 요법을 위한 치환된 페닐옥사졸리디논

Also Published As

Publication number Publication date
NZ738702A (en) 2023-09-29
JP6786598B2 (ja) 2020-11-18
KR102511898B1 (ko) 2023-03-20
AU2021205116B2 (en) 2022-11-10
ES2897973T3 (es) 2022-03-03
EP3307268A1 (en) 2018-04-18
US20200148651A1 (en) 2020-05-14
CN108348507A (zh) 2018-07-31
US10550092B2 (en) 2020-02-04
JP2020122016A (ja) 2020-08-13
AU2016295165B2 (en) 2021-04-22
EP3932917A3 (en) 2022-03-30
EA037643B1 (ru) 2021-04-26
JP7232212B2 (ja) 2023-03-02
CA2990260A1 (en) 2017-01-26
US11964949B2 (en) 2024-04-23
US20180179168A1 (en) 2018-06-28
KR20180026491A (ko) 2018-03-12
AU2022268387A1 (en) 2022-12-15
AU2021205116A1 (en) 2021-08-12
AU2016295165A1 (en) 2018-01-25
EP3307268B1 (en) 2021-09-01
JP2018524406A (ja) 2018-08-30
JP2021183647A (ja) 2021-12-02
EP3307268A4 (en) 2019-01-09
BR112018000991A2 (pt) 2018-12-04
CN108348507B (zh) 2021-10-08
CN113603683A (zh) 2021-11-05
JP2023133610A (ja) 2023-09-22
EA201792566A1 (ru) 2018-10-31
WO2017015106A1 (en) 2017-01-26
HK1255105A1 (zh) 2019-08-02
EP3932917A2 (en) 2022-01-05
ZA201800189B (en) 2019-06-26

Similar Documents

Publication Publication Date Title
EA202190167A1 (ru) Замещенные фенилоксазолидиноны для антимикробной терапии
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
MX2017000408A (es) Compuestos antiproliferativos y métodos de uso de los mismos.
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
BR112015027699A2 (pt) Uso de robenidina ou um sal terapeuticamente aceitável da mesma, composição farmacêutica antibacteriana e dispositivo médico
NZ751197A (en) Compounds and methods of treating infections
AR103680A1 (es) Inhibidores selectivos de bace1
EA201791069A1 (ru) Комбинированная терапия для лечения устойчивых бактериальных инфекций
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
TR201903892T4 (tr) Diyabet ve obezitenin tedavisinde kullanılan dihidrobenzofuran bileşikleri.
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
PH12017500290A1 (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
EA201890614A1 (ru) Комбинированная антибактериальная композиция и короткий курс антибактериальной терапии